[Laboratory markers of melanoma progression].
Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immune complex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropriate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.
Bánfalvi
Teodóra
T
Országos Onkológiai Intézet, Budapest, Hungary.
Edesné
Mariann B
MB
Gergye
Mária
M
Udvarhelyi
Nóra
N
Orosz
Zsolt
Z
Gilde
Katalin
K
Kremmer
Tibor
T
Ottó
Szabolcs
S
Tímár
József
J
D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood; D002570:Ceruloplasmin / Q000378:metabolism; D003300:Copper / Q000097:blood; D016207:Cytokines / Q000097:blood; D018450:Disease Progression; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008543:Melanins / Q000096:biosynthesis; D008545:Melanoma / Q000097:blood*; D008666:Metalloendopeptidases / Q000097:blood; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000097:blood*; D015032:Zinc / Q000097:blood
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D016207:Cytokines; D008543:Melanins; D003300:Copper; D007770:L-Lactate Dehydrogenase; D002570:Ceruloplasmin; D008666:Metalloendopeptidases; D015032:Zinc
A melanoma progressziójának laboratóriumi markerei.